Drugs / Avosentan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00120328 | Jul 2005 → Feb 2007 | diabetic kidney disease | Speedel Pharma Ltd. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avosentan | “To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy” NCT00120328 ↗ |
| Known as | RO 67-0565 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989834 ↗ |
| Known as | SPP301 | “The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.” NCT00120328 ↗ |
| Action | Inhibit | “Endothelin Receptor Antagonist Avosentan” NCT00120328 ↗1“Endothelin receptor ET-A antagonist” CHEMBL3989834 ↗ |
| Modality | Small molecule | — CHEMBL3989834 ↗ |
| Target | EDNRA | “Endothelin receptor ET-A antagonist” CHEMBL3989834 ↗ |